Caudatin

Synonyms: 告达亭苷元
Caudatin 是一种具有口服活性且可穿透血脑屏障的 C-21 甾体类化合物,存在于白首乌 (Cynanchum bungei decne) 中,具有多种生物学活性:它可抑制细胞增殖、迁移和侵袭,引发细胞周期阻滞,诱导凋亡 (apoptosis)、自噬 (autophagy)、活性氧 (ROS) 产生及线粒体膜电位丧失,激活 PARP、caspase-3、-7、-9,上调促凋亡蛋白 Bad 和 Bax 的表达,下调抗凋亡蛋白 Bcl-2 和 Bcl-XL 的表达,抑制 VEGF、FAK 的磷酸化,上调 p21、p27、DR5 的蛋白表达,并激活 p38 MAPK、JNK 以及 PPARα/TFEB 介导的自噬-溶酶体信号通路,因此可用于癌症、炎症及神经系统疾病(如胶质瘤、阿尔茨海默病)的研究。
产品编号: MS-X88650 纯度: 99.95% CAS No.: 38395-02-7 分子式: C28H42O7 分子量: 490.63
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Caudatin 是一种具有口服活性且可穿透血脑屏障的 C-21 甾体类化合物,存在于白首乌 (Cynanchum bungei decne) 中,具有多种生物学活性:它可抑制细胞增殖、迁移和侵袭,引发细胞周期阻滞,诱导凋亡 (apoptosis)、自噬 (autophagy)、活性氧 (ROS) 产生及线粒体膜电位丧失,激活 PARP、caspase-3、-7、-9,上调促凋亡蛋白 Bad 和 Bax 的表达,下调抗凋亡蛋白 Bcl-2 和 Bcl-XL 的表达,抑制 VEGF、FAK 的磷酸化,上调 p21、p27、DR5 的蛋白表达,并激活 p38 MAPK、JNK 以及 PPARα/TFEB 介导的自噬-溶酶体信号通路,因此可用于癌症、炎症及神经系统疾病(如胶质瘤、阿尔茨海默病)的研究。

生物实验数据

生物活性 Caudatin is an orally active, blood-brain barrier-permeable C-21 steroidal compound found in Cynanchum bungei decne that exhibits multiple biological activities: it inhibits cell proliferation, migration, and invasion, induces cell cycle arrest, apoptosis, autophagy, reactive oxygen species (ROS) production, and loss of mitochondrial membrane potential, activates PARP and caspase-3, -7, and -9, upregulates the expression of pro-apoptotic proteins Bad and Bax, downregulates the expression of anti-apoptotic proteins Bcl-2 and Bcl-XL, inhibits the phosphorylation of VEGF and FAK, upregulates the protein expression of p21, p27, and DR5, and activates p38 MAPK, JNK, and the PPARα/TFEB-mediated autophagy-lysosomal signaling pathway, making it useful for research on cancer, inflammation, and neurological diseases such as glioma and Alzheimer's disease.
IC50 & Target

Caspase 3

 

Caspase-7

 

Caspase-9

 

Bax

 

Bcl-xL

 

Bcl-2

 

bad

 

体外研究
(In Vitro)

Caudatin (25-100 μM; 24-72 h) 可以时间和剂量依赖的方式强效抑制人胶质瘤 U251 和 U87 细胞的活性,其中 U251 细胞的敏感性更高 (72 h 时 IC50 = 52.1 μM)。
Caudatin (25-100 μM; 72 h) 可在人胶质瘤 U251 细胞中诱导剂量依赖性凋亡,当以 100 μM Caudatin 处理 72 h 后,有 71.4%的细胞发生凋亡。
Caudatin (12.5-100 μM; 72 h) 可在 72 h 内诱导人胶质瘤 U251 细胞中呈剂量依赖性的 PARP 切割,以及 caspase-3、caspase-7 和 caspase-9 的活化。
Caudatin (25-100 μM; 5-30 min) 可在人胶质瘤 U251 细胞中诱导线粒体膜电位呈时间依赖性丧失。
Caudatin (25-100 μM; 1-72 h) 可破坏人胶质瘤 U251 细胞中 Bcl-2 家族蛋白的平衡,在 72 h 内以剂量依赖方式上调促凋亡蛋白 Bad 和 Bax,同时下调抗凋亡蛋白 Bcl-2 和 Bcl-XL。
Caudatin (25-100 μM; 2-72 h) 可通过诱导呈剂量依赖性的 ROS 和超氧化物积累、降低线粒体质量及 GSH 含量,扰乱人胶质瘤 U251 细胞内的氧化还原稳态。
Caudatin (6-200 μM; 48 h) 可呈剂量依赖性抑制 HUVEC 的增殖,在处理 48 h 后,50、100 和 200 μM 浓度分别将细胞活力降至 71.5%、53.6%和 38.1%。
Caudatin (100 μM; 48 h) 处理 48 h 后可抑制 HUVEC 的迁移。
Caudatin (100 μM; 24 h) 处理 24 h 后可抑制 HUVEC 的侵袭。
Caudatin (100 μM; 24 h) 处理 24 h 后可抑制 HUVEC 的毛细血管样管形成。
Caudatin (50-200 μM; 12-48 h) 可以剂量依赖和时间依赖的方式抑制人脐静脉内皮细胞 (HUVECs) 中 FAK 的磷酸化。
Caudatin (50-200 μM; 48 h) 可以剂量依赖的方式抑制 HUVEC 中 VEGF 和磷酸化 VEGFR2 的表达,且不改变总 VEGFR2 或 AKT 的水平。
Caudatin (5-100 μg/mL; 24 h) 可呈浓度依赖性抑制人 MDA-MB-231 和 MCF-7 乳腺癌细胞的活力。
Caudatin (10-50 μg/mL; 24 h) 可诱导人 MDA-MB-231 和 MCF-7 乳腺癌细胞发生 G1 期细胞周期阻滞。
Caudatin (5-50 μg/mL; 24 h) 可调控关键细胞周期调控因子的表达,包括在人 MDA-MB-231 和 MCF-7 乳腺癌细胞中上调 p21、p27 及 p53,同时下调 p-Cdc2、Cdk4 和 cyclinB1。
Caudatin (5-50 μg/mL; 24 h) 可诱导人 MDA-MB-231 和 MCF-7 乳腺癌细胞发生细胞凋亡,caspase-8、caspase-9 和 PARP 的剂量依赖性剪切可证明这一点。
Caudatin (5-50 μg/mL; 24 h) 可在人 MDA-MB-231 和 MCF-7 乳腺癌细胞中以剂量依赖方式上调 DR5 蛋白表达,且不影响 DR4 的表达。
Caudatin (5-50 μg/mL; 24 h) 可激活人 MDA-MB-231 和 MCF-7 乳腺癌细胞中的内质网应激反应,PERK、BIP、ATF4 和 CHOP 蛋白水平呈剂量依赖性上调可证明这一点。
Caudatin (5-50 μg/mL; 24 h) 可在人 MDA-MB-231 和 MCF-7 乳腺癌细胞中以剂量依赖的方式激活 p38 MAPK 和 JNK 信号通路,且不影响 ERK1/2 的磷酸化。
Caudatin (10-50 μg/mL; 24 h) 可诱导人 MDA-MB-231 和 MCF-7 乳腺癌细胞发生细胞凋亡。
Caudatin 可与人类 PPARα 配体结合域强结合。
Caudatin (25 μM; 24 h) 可逆转 Aβ1-42 诱导的小鼠海马神经元 HT-22 细胞毒性。
Caudatin (6.25-25 μM; 24 h) 呈剂量依赖性诱导小鼠神经细胞发生自噬并促进自噬流。
Caudatin (25 μM; 24 h) 可诱导小鼠小胶质细胞中 PPARα 的核转位,该效应可被 PPARα 抑制剂 GW6471 (MS-V40693) 阻断。
Caudatin (25 μM) 以 PPARα 依赖的方式降低过表达 AD 相关突变的小鼠小胶质细胞中的磷酸化 Tau 蛋白和 APP 代谢物。
Caudatin (6.25-25 μM) 可通过不依赖 MTORC1 的机制,以剂量依赖方式上调小鼠神经元细胞和小胶质细胞中 TFEB 的表达并诱导 TFEB 发生核转位。

Cell Viability Assay

Cell Line: human glioma U251, U87 cells
Concentration: 25, 50, 100 μM
Incubation Time: 24 h; 48 h; 72 h
Result: Significantly decreased U251 and U87 cell viability in a time- and dose-dependent manner.
Reduced U251 cell viability to 73.5%, 51.3%, and 28.2% after treatment with 25, 50, 100 μM for 72 h, respectively.
Exhibited IC50 values towards U251 cells of 170.3 μM (24 h), 102.2 μM (48 h), and 52.1 μM (72 h).

Apoptosis Analysis

Cell Line: human glioma U251 cells
Concentration: 25, 50, 100 μM
Incubation Time: 72 h
Result: Induced significant dose-dependent apoptosis in U251 cells, as measured by the Sub-G1 peak.
Resulted in 10.2%, 34.7%, and 71.4% apoptotic cells after treatment with 25, 50, 100 μM, respectively.

Western Blot Analysis

Cell Line: human glioma U251 cells
Concentration: 12.5, 25, 50, 100 μM
Incubation Time: 72 h
Result: Dose-dependently induced PARP cleavage (89 KD fragment) and activation of caspase-3, caspase-7, and caspase-9 in U251 cells.
Resulted in PARP cleavage levels (normalized to β-actin) of 0.1, 0.5, 0.9, and 1.0 for 12.5, 25, 50, and 100 μM, respectively.
Resulted in active caspase-3 levels of 0.4, 0.4, 0.5, and 1.0 for 12.5, 25, 50, and 100 μM, respectively.
Resulted in active caspase-7 levels of 0.5, 0.9, and 1.0 for 25, 50, and 100 μM, respectively.
Resulted in active caspase-9 levels of 0.5, 0.7, and 1.0 for 25, 50, and 100 μM, respectively.

Western Blot Analysis

Cell Line: human glioma U251 cells
Concentration: 25, 50, 100 μM (72 h treatment); 50 μM (time-course treatment)
Incubation Time: 72 h; 1, 6, 12, 24, 48, 72 h (time-course)
Result: Dose-dependently upregulated pro-apoptotic Bad and Bax expression, and downregulated anti-apoptotic Bcl-2 and Bcl-XL expression in U251 cells after 72 h treatment.
Decreased Bcl-2 expression (normalized to β-actin) to 0.9, 0.9, 0.8, 0.1, 0.1, and 0.1 at 1, 6, 12, 24, 48, and 72 h, respectively, with 50 μM treatment.
Increased Bad expression to 0.6, 0.7, 0.8, and 1.0 at 12, 24, 48, and 72 h, respectively, with 50 μM treatment.

Apoptosis Analysis

Cell Line: human glioma U251 cells
Concentration: 50 μM (with 20 μM caspase inhibitor pretreatment)
Incubation Time: 72 h
Result: Reduced 50 μM caudatin-induced apoptosis from 32.4% to 7.4% when cells were pretreated with z-VAD-fmk, and increased cell viability in caudatin-treated cells.
Suppressed caudatin-induced PARP cleavage when cells were pretreated with z-VAD-fmk or z-LEHD-fmk.
Suppressed caudatin-induced activation of caspase-3, caspase-7, and caspase-9 when cells were pretreated with z-VAD-fmk or z-DEVD-fmk.

Cell Viability Assay

Cell Line: human umbilical vein endothelial cells (HUVECs)
Concentration: 6, 12, 25, 50, 100, 200 μM
Incubation Time: 48 h
Result: Slightly promoted HUVEC growth at 6 μM.
Significantly inhibited HUVEC viability in a dose-dependent manner at 25, 50, 100, 200 μM, reducing viability to 71.5% (50 μM), 53.6% (100 μM), and 38.1% relative to control.

Western Blot Analysis

Cell Line: human umbilical vein endothelial cells (HUVECs)
Concentration: 50, 100, 200 μM (dose-dependent assay); 100 μM (time-dependent assay)
Incubation Time: 48 h; 12, 24, 48 h (time-dependent assay)
Result: Reduced p-FAK levels in a dose-dependent manner at 50, 100, 200 μM after 48 h.
Reduced p-FAK levels in a time-dependent manner at 100 μM after 12, 24, and 48 h.

Western Blot Analysis

Cell Line: human umbilical vein endothelial cells (HUVECs)
Concentration: 50, 100, 200 μM
Incubation Time: 48 h
Result: Reduced VEGF and p-VEGFR2 expression in a dose-dependent manner after 48 h, with no significant changes in total VEGFR2 or total AKT levels.

Cell Cycle Analysis

Cell Line: human MDA-MB-231 and MCF-7 breast carcinoma cells
Concentration: 10, 50 μg/mL
Incubation Time: 24 h
Result: Increased the G1-phase population to 64.78±0.98% and decreased the G2/M-phase population to 17.75±0.66% in MDA-MB-231 cells at 10 μg/mL.
Increased the G1-phase population to 69.76±1.83% and decreased the G2/M-phase population to 11.10±1.14% in MDA-MB-231 cells at 50 μg/mL.
Increased the G1-phase population to 57.14±1.11% and decreased the S-phase population to 34.05±1.26% in MCF-7 cells at 10 μg/mL.
Increased the G1-phase population to 73.94±2.01% and decreased the S-phase population to 14.99±1.24% in MCF-7 cells at 50 μg/mL.

Western Blot Analysis

Cell Line: human MDA-MB-231 and MCF-7 breast carcinoma cells
Concentration: 5-50 μg/mL
Incubation Time: 24 h
Result: Caused dose-dependent accumulation of p21 and p27 proteins in both cell lines.
Upregulated p53 protein in MCF-7 cells but not in MDA-MB-231 cells.
Downregulated p-Cdc2, Cdk4, and cyclinB1 proteins in both cell lines.
Left Cdc2 protein levels unchanged in both cell lines.
Caused dose-dependent cleavage of caspase-8, caspase-9, and PARP, hallmark features of apoptosis, in both cell lines.
Caused a dose-dependent increase in DR5 protein levels in both cell lines, with no significant change in DR4 protein levels observed.
Caused a dose-dependent increase in protein levels of PERK, BIP, ATF4, and CHOP, markers of ER stress and the unfolded protein response, in both cell lines.
Caused a dose-dependent increase in phosphorylation of p38 MAPK and JNK in both cell lines, with no significant change in ERK1/2 phosphorylation observed.

Cell Autophagy Assay

体内研究
(In Vivo)

Caudatin (25-50 mg/kg;静脉注射;每 2 天 1 次;持续 16 天) 可通过诱导细胞凋亡、抑制细胞增殖及阻断血管生成,显著抑制雄性裸鼠体内 U251 人胶质瘤异种移植物的生长,且对小鼠体重无明显影响。
Caudatin (25-50 mg/kg;静脉注射;隔日一次;连续 16 天) 可剂量依赖性地抑制雄性裸鼠皮下 U251 胶质瘤移植瘤的生长;同时该药物可通过下调 VEGF 表达、CD34 阳性血管密度以及 p-AKT/p-FAK 水平来抑制血管生成。
Caudatin (20-40 mg/kg;口服;每日给药,持续 8 个月) 可改善 3XTg-AD 小鼠的认知功能,减少 Aβ 和病理性 Tau 病理改变,激活 PPARα/TFEB 介导的自噬-溶酶体通路,并减轻其神经炎症。
Caudatin (20 mg/kg;灌胃;单次给药) 可透过健康 ICR 小鼠的血脑屏障,在 15 分钟时脑内浓度达峰值 64.77 ng/g。

Animal Model: Nude mice with U251 human glioma xenograft (male)
Dosage: 25 mg/kg; 50 mg/kg
Administration: i.v.; every other day; 16 days
Result: Reduced tumor volume and tumor weight compared to control.
Induced tumor cell apoptosis (via caspase-3 activation).
Inhibited tumor cell proliferation (via reduced Ki-67 staining).
Suppressed tumor angiogenesis (via reduced CD-31 staining).
Did not affect mouse body weight.
Animal Model: Nude mice with U251 human glioma xenograft (male)
Dosage: 25 mg/kg; 50 mg/kg
Administration: i.v.; every other day; 16 days
Result: Reduced mean tumor volume and mean tumor weight.
Dose-dependently reduced phosphorylated AKT (p-AKT) and phosphorylated FAK (p-FAK) levels in tumor tissue.
Dose-dependently decreased immunohistochemical staining of Ki-67, VEGF, and CD34 in tumor tissue.
Animal Model: 3XTg-AD (female, 6 months old, Alzheimer's disease model with K670M/N671L, M146V, P301L mutant gene overexpression); 129/B6/SWJ (female, wildtype littermate)
Dosage: 20 mg/kg; 40 mg/kg
Administration: p.o.; daily; 8 months
Result: Reduced escape latency in the Morris water maze (MWM) task, increased time spent in the target quadrant during the MWM probe trial, increased freezing percentage in the contextual fear conditioning test, reduced time spent in the center of the open field chamber, and increased total distance traveled in the open field test compared to vehicle-treated 3XTg-AD mice.
Reduced AT8-positive neuron load in hippocampal brain slices; significantly lowered sarkosyl-insoluble levels of pathological Tau markers PHF1, AT8, CP13, MC1, and HT7 in brain homogenates.
Reduced the number of 4G8-positive Aβ plaques in hippocampal brain slices; significantly lowered formic acid-soluble Aβ1-42 and Aβ1-40 levels in brain homogenates, and reduced SDS-soluble levels of APP metabolites CTFs and pCTFs.
Increased brain homogenate protein levels of PPARα, TFEB, mature CTSD, LAMP1, and LC3B-II, while reducing SQSTM1 levels, compared to vehicle-treated 3XTg-AD mice.
Reduced the number of activated microglia and astrocytes in brain slices, and lowered corresponding protein levels in brain homogenates.
性状 固体
颜色 White to off-white

化学信息

分子量 490.63
分子式 C28H42O7
CAS No. 38395-02-7
别名 告达亭苷元

储存&溶解度

体内实验配方
10% DMSO+90% Saline: < 10 mg/mL (20.38 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (20.38 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (101.91 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.0382 mL10.1910 mL20.3820 mL50.9549 mL
5 mM0.4076 mL2.0382 mL4.0764 mL10.1910 mL
10 mM0.2038 mL1.0191 mL2.0382 mL5.0955 mL
15 mM0.1359 mL0.6794 mL1.3588 mL3.3970 mL
20 mM0.1019 mL0.5095 mL1.0191 mL2.5477 mL
25 mM0.0815 mL0.4076 mL0.8153 mL2.0382 mL
30 mM0.0679 mL0.3397 mL0.6794 mL1.6985 mL
40 mM0.0510 mL0.2548 mL0.5095 mL1.2739 mL
50 mM0.0408 mL0.2038 mL0.4076 mL1.0191 mL
60 mM0.0340 mL0.1698 mL0.3397 mL0.8492 mL
80 mM0.0255 mL0.1274 mL0.2548 mL0.6369 mL
100 mM0.0204 mL0.1019 mL0.2038 mL0.5095 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

告达亭苷元 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础